Skip to main content

Table 2 Univariate Analysis of Prognostic Factors of GBMSS and OS in GBM

From: Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis

Characteristic

HR

GBMSS

p

HR

OS

p

95%CI

95%CI

Age at diagnosis

 Young

1

  

1

  

 Adult

1.016

0.8814–1.171

0.8270

1.278

1.119–1.460

0.0003

 Old

1.98

1.7172–2.284

< 0.0001

2.632

2.304–3.007

< 0.0001

Gender

 Female

1

  

1

  

 Male

0.950

0.923–0.978

0.0005

1.003

0.9769–1.029

0.8470

Race

 White

1

  

1

  

 Black

0.9173

0.861–0.9773

0.0076

0.9072

0.8578–0.9594

0.0007

 American indian/alaska native

0.9074

0.7295–1.1288

0.3831

0.9158

0.7486–1.1203

0.3922

 Asian of pacific islander

0.8523

0.7945–0.9143

< 0.0001

0.8251

0.7744–0.8791

< 0.0001

 Unknown

1.2114

0.7974–1.840

0.3687

0.6008

0.4174–0.8647

0.0061

Primary site

 Supratentorial

1

  

1

  

 Infratentorial

1.185

1.1385–1.233

< 0.0001

1.206

0.8289–1.1639

< 0.0001

 Brain overlap

1.099

0.9628–1.255

0.1620

1.043

0.9586–0.9306

0.4680

Size

  ≤ 4 cm

1

  

1

  

  > 4 cm

1.08

1.047–1.114

< 0.0001

1.079

1.05–1.109

< 0.0001

Surgery

 Yes

1

  

1

  

 No

2.186

2.109–2.265

< 0.0001

2.287

2.216–2.360

< 0.0001

 Unknown

1.814

1.289–2.552

0.0006

1.761

1.296–2.392

0.0003

Radiation

 Yes

1

  

1

  

 No

2.41

2.338–2.485

< 0.0001

2.514

2.447–2.583

< 0.0001

Chemotherapy

 Yes

1

  

1

  

 No

2.617

2.545–2.691

< 0.0001

2.571

2.438–2.599

< 0.0001

  1. Abbreviations: HR Hazardous Ratio, CI Credential Interval, OS overall survival, GBMSS GBM specific survival